FORT LAUDERDALE, Fla. — The proportion of patients with a 2 or more-step improvement in non-proliferative diabetic retinopathy scores was significantly greater when treated with aflibercept compared to a sham, according to a speaker here.
“PANORAMA is the first large, prospective trial of high risk, non-proliferative diabetic retinopathy patients since the Early Treatment Diabetic Retinopathy Study,” W. Lloyd Clark, MD, said at the Retina World Congress.
Clark presented the 52-week results of the PANORAMA study, a phase 3, double-masked study that evaluated the efficacy and
Uncategorized